GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

Search

AstraZeneca PLC

Gesloten

SectorGezondheidszorg

10,440 -1.75

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10434

Max

10458

Belangrijke statistieken

By Trading Economics

Inkomsten

1.3B

2.9B

Verkoop

-1.3B

14B

K/W

Sectorgemiddelde

28.071

39.564

Dividendrendement

2.43

Winstmarge

21.46

Werknemers

94,300

EBITDA

648M

5.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+26.98% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.43%

2.40%

Volgende Winsten

29 jul 2025

Volgende dividenddatum

8 sep 2025

Volgende Ex Dividend datum

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-24B

158B

Vorige openingsprijs

10441.75

Vorige sluitingsprijs

10440

Nieuwssentiment

By Acuity

61%

39%

319 / 376 Rangschikking in Healthcare

AstraZeneca PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2025, 09:36 UTC

Belangrijke Marktbewegers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 apr 2025, 10:14 UTC

Winsten

Correction to AstraZeneca Update

29 apr 2025, 09:15 UTC

Winsten

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 apr 2025, 08:12 UTC

Winsten

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 apr 2025, 06:32 UTC

Winsten

AstraZeneca Sales, Earnings Rise

9 jul 2025, 10:59 UTC

Marktinformatie

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Populaire aandelen

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New -2-

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 mei 2025, 06:09 UTC

Acquisities, Fusies, Overnames

AstraZeneca Completes Acquisition of EsoBiotec

12 mei 2025, 12:07 UTC

Marktinformatie

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mei 2025, 07:20 UTC

Marktinformatie

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 mei 2025, 15:20 UTC

Winsten

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 apr 2025, 13:09 UTC

Marktinformatie
Winsten

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 apr 2025, 08:04 UTC

Marktinformatie
Winsten

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 apr 2025, 06:05 UTC

Winsten

AstraZeneca 1Q Core EPS $2.49

29 apr 2025, 06:04 UTC

Winsten

AstraZeneca 1Q Net Pft $2.92B

29 apr 2025, 06:02 UTC

Winsten

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca Backs 2025 View

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q EPS $1.87

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Rev $13.59B

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Oper Pft $3.67B

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 apr 2025, 09:55 UTC

Marktinformatie

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 apr 2025, 07:23 UTC

Marktinformatie

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 apr 2025, 08:41 UTC

Marktinformatie

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 apr 2025, 08:36 UTC

Marktinformatie

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 apr 2025, 07:51 UTC

Marktinformatie

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

Peer Vergelijking

Prijswijziging

AstraZeneca PLC Prognose

Koersdoel

By TipRanks

26.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13,269.69 GBX  26.98%

Hoogste 16,500 GBX

Laagste 10,900 GBX

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Sentiment

By Acuity

319 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.